The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Bent Ejlertsen

Danish Breast Cancer Cooperative Group Statistical Center; Department of Oncology


Copenhagen University Hospital




Name/email consistency: high



  • Danish Breast Cancer Cooperative Group Statistical Center; Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. 2012
  • Danish Breast Cancer Cooperative Group, Copenhagen, Denmark. 2010
  • Department of Oncology, Bldg 4262 Rigshospitalet, 9, Blegdamsvej, DK-2100 Copenhagen, Denmark. 2003 - 2010


  1. Prognostic and predictive role of ESR1 status for postmenopausal patients with endocrine-responsive early breast cancer in the Danish cohort of the BIG 1-98 trial. Ejlertsen, B., Aldridge, J., Nielsen, K.V., Regan, M.M., Henriksen, K.L., Lykkesfeldt, A.E., Müller, S., Gelber, R.D., Price, K.N., Rasmussen, B.B., Viale, G., Mouridsen, H. Ann. Oncol. (2012) [Pubmed]
  2. Cyclophosphamide, methotrexate, and fluorouracil; oral cyclophosphamide; levamisole; or no adjuvant therapy for patients with high-risk, premenopausal breast cancer. Ejlertsen, B., Mouridsen, H.T., Jensen, M.B., Andersen, J., Andersson, M., Kamby, C., Knoop, A.S. Cancer (2010) [Pubmed]
  3. HER2, TOP2A, and TIMP-1 and responsiveness to adjuvant anthracycline-containing chemotherapy in high-risk breast cancer patients. Ejlertsen, B., Jensen, M.B., Nielsen, K.V., Balslev, E., Rasmussen, B.B., Willemoe, G.L., Hertel, P.B., Knoop, A.S., Mouridsen, H.T., Brünner, N. J. Clin. Oncol. (2010) [Pubmed]
  4. Population-based study of peritumoral lymphovascular invasion and outcome among patients with operable breast cancer. Ejlertsen, B., Jensen, M.B., Rank, F., Rasmussen, B.B., Christiansen, P., Kroman, N., Kvistgaard, M.E., Overgaard, M., Toftdahl, D.B., Mouridsen, H.T. J. Natl. Cancer Inst. (2009) [Pubmed]
  5. Improved outcome from substituting methotrexate with epirubicin: results from a randomised comparison of CMF versus CEF in patients with primary breast cancer. Ejlertsen, B., Mouridsen, H.T., Jensen, M.B., Andersen, J., Cold, S., Edlund, P., Ewertz, M., Jensen, B.B., Kamby, C., Nordenskjold, B., Bergh, J. Eur. J. Cancer (2007) [Pubmed]
  6. Similar efficacy for ovarian ablation compared with cyclophosphamide, methotrexate, and fluorouracil: from a randomized comparison of premenopausal patients with node-positive, hormone receptor-positive breast cancer. Ejlertsen, B., Mouridsen, H.T., Jensen, M.B., Bengtsson, N.O., Bergh, J., Cold, S., Edlund, P., Ewertz, M., de Graaf, P.W., Kamby, C., Nielsen, D.L. J. Clin. Oncol. (2006) [Pubmed]
  7. Phase III study of intravenous vinorelbine in combination with epirubicin versus epirubicin alone in patients with advanced breast cancer: a Scandinavian Breast Group Trial (SBG9403). Ejlertsen, B., Mouridsen, H.T., Langkjer, S.T., Andersen, J., Sjöström, J., Kjaer, M. J. Clin. Oncol. (2004) [Pubmed]
  8. Combined epirubicin and vinorelbine as first-line therapy in metastatic breast cancer: a pilot study performed by the Danish Breast Cancer Cooperative Group. Ejlertsen, B., Højris, I., Hansen, S., Møholt, K., Kristensen, B., Mouridsen, H.T., Andersen, J., Rose, C., Kjaer, M. Breast (2003) [Pubmed]
WikiGenes - Universities